Trial Profile

Phase II Study of Imatinib Mesylate as Adjuvant Treatment in High-Relapse Risk Localized Gastrointestinal Stromal Tumors With c-Kit Mutation

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imatinib (Primary)
Indications Gastrointestinal stromal tumours
Focus Therapeutic Use

Most Recent Events

18 Apr 2013 Actual end date changed from Aug 2007 to Mar 2011 as reported by ClinicalTrials.gov.
28 Nov 2007 Status changed from recruiting to completed.
18 Nov 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com